Jild 3 № 3 (2026): Iyul - sentyabr
11-21
2026-09-30
Ochiq kirish

Yurak ishemik kasalligi bilan og‘rigan bemorlarda lipid almashinuvining genetik variantlari bilan triglitseridlarga boy lipoproteinlar darajasi va aralash dislipidemiya o‘rtasidagi o‘zaro bog‘liqlikni baholash.

Malika U.Yaxyoeva
Rano B.Alieva
Aleksandr B.Shek
A.V. Bahachova
https://doi.org/10.70626/cardiouz-2026-3-00094

Qabul qilingan: 2026-09-15

Nashr etilgan: 2026-09-30

PDF (ruscha)
Crossmark Crossmark

Annotatsiya

Maqsad. Yurak ishemik kasalligi (YuIK) bilan og‘rigan bemorlarda xolesterin (XS) almashinuvini, xususan, XS PZLP metabolizmini tartibga soluvchi genlar (LDLR, APOB, PCSK9), triglitseridlar (TG) almashinuvini belgilovchi genlar (LPL, APOC3) variantlari va ularning kombinatsiyalarining triglitseridlarga boy lipoproteinlar darajasi bilan o‘zaro bog‘liqligini baholash, TG va XS PZLP darajalarining bir vaqtda oshishi bilan kechuvchi aralash dislipidemiya fenotipida ko‘proq uchraydigan genetik kombinatsiyalarni aniqlash, shuningdek, ularning glyukoza, insulin, tana massasi indeksi (TMI) va bel aylanasining ko‘rsatkichlari bilan o‘zaro ta’sirini baholash.
Materiallar va usullar. Tadqiqotga YuIK bilan og‘rigan 66 nafar bemor kiritildi. Ularda yuqorida ko‘rsatilgan genetik polimorfizmlar NGS usuli yordamida o‘rganildi, shuningdek, antropometrik va biokimyoviy ko‘rsatkichlar baholandi.
Natijalar. YuIK bilan og‘rigan 66 nafar bemordan iborat guruhda APOC3 c.102T>C + APOB p.Ser4338Asn genetik polimorfizmlari kombinatsiyasi eng ko‘p uchradi va aralash dislipidemiyaning (bir vaqtning o'zida TG ≥150 mg/dl (≥1,7 mmol/l) va XS PZLP ≥100 mg/dl (≥2,6 mmol / l) ko‘proq uchrashiga moyillikni namoyon etdi, bu, ehtimol, kuzatuvlar sonining kamligi bilan izohlanadi. Bel aylanasi, TMI, glyukoza va insulin darajalari o‘rganilgan umumiy genotipik kombinatsiyalarning aksariyatiga nisbatan TG bilan yanada izchil bog‘liqlikni namoyon etdi. Olingan natijalar genetik moyillikning insulinrezistentlik va semirish bilan o‘zaro ta’sirlashuvi modelini qo‘llab-quvvatlaydi.
Xulosa. APOC3 c.102T>C + APOB p.Ser4338Asn variantlari kombinatsiyasi aralash dislipidemiya bilan bog’lanish moyillikni namoyon qildi, biroq uni isbotlangan genetik prediktor sifatida ko‘rib chiqish mumkin emas. Olingan natijalar dastlabki xususiyatga ega bo‘lib, ularni kattaroq tanlanma hajmida hamda genetik variantlarning funksional xususiyatlarini baholash orqali tasdiqlash talab etiladi.

Kalit so‘zlar

Adabiyotlar ro'yxati

  1. Aceves-Ramírez, M., Valle, Y., Casillas-Muñoz, F., Martínez-Fernández, D. E., Parra-Reyna, B., López-Moreno, V. A., Flores-Salinas, H. E., Valdés-Alvarado, E., Muñoz-Valle, J. F., García-Garduño, T., & Padilla-Gutiérrez, J. R. (2022). Analysis of the APOB Gene and Apolipoprotein B Serum Levels in a Mexican Population with Acute Coronary Syndrome: Association with the Single Nucleotide Variants rs1469513, rs673548, rs676210, and rs1042034. Genetics research, 2022, 4901090. https://doi.org/10.1155/2022/4901090

  2. Anne-Marie K Jepsen, Anne Langsted, Anette Varbo, Lia E Bang, Pia R Kamstrup, Børge G Nordestgaard, Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease, Clinical Chemistry, Volume 62, Issue 4, 1 April 2016, Pages 593–604, https://doi.org/10.1373/clinchem.2015.253757

  3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), https://doi.org/10.1093/eurheartj/ehz455

  4. Giammanco, A., Spina, R., Cefalù, A.B. et al. APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism. Curr Atheroscler Rep 25, 67–76 (2023). https://doi.org/10.1007/s11883-023-01080-8

  5. Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard, B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M. R., Tokgözoğlu, L. S., Tybjaerg-Hansen, A., … Catapano, A. L. (2021). Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. European heart journal, 42(47), 4791–4806. https://doi.org/10.1093/eurheartj/ehab551

  6. Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014). Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. The New England journal of medicine, 371(1), 32–41. https://doi.org/10.1056/NEJMoa1308027

  7. Lawler, P. R., Akinkuolie, A. O., Chu, A. Y., Shah, S. H., Kraus, W. E., Craig, D., Padmanabhan, L., Glynn, R. J., Ridker, P. M., Chasman, D. I., & Mora, S. (2017). Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. Journal of the American Heart Association, 6(7), e005549. https://doi.org/10.1161/JAHA.117.005549

  8. Mansilla-Rodríguez, M. E., Sánchez-Ramos, J. L., Sánchez-Junco, A. R., Pang, J., Chan, D. C., Gutiérrez-Cortizo, E. N., Mata, P., Watts, G. F., & Romero-Jiménez, M. J. (2026). Risk factors for atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. Atherosclerosis, 415, 120650. https://doi.org/10.1016/j.atherosclerosis.2026.120650

  9. Philippa J. Talmud, Emma Hawe, Steve Martin, Michael Olivier, George J. Miller, Edward M. Rubin, Len A. Pennacchio, Steve E. Humphries, Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides, Human Molecular Genetics, Volume 11, Issue 24, 15 November 2002, Pages 3039–3046, https://doi.org/10.1093/hmg/11.24.3039

  10. Rout, M., Lerner, M., Blackett, P. R., Peyton, M. D., Stavrakis, S., Sidorov, E., & Sanghera, D. K. (2022). Ethnic differences in ApoC-III concentration and the risk of cardiovascular disease: No evidence for the cardioprotective role of rare/loss of function APOC3 variants in non-Europeans. American heart journal plus: cardiology research and practice, 13, 100128. https://doi.org/10.1016/j.ahjo.2022.100128

  11. Salinas, C. A. A., & Chapman, M. J. (2020). Remnant lipoproteins: are they equal to or more atherogenic than LDL?. Current opinion in lipidology, 31(3), 132–139. https://doi.org/10.1097/MOL.0000000000000682

  12. Vanuzzo, D. The epidemiological concept of residual risk. Intern Emerg Med 6 (Suppl 1), 45 (2011). https://doi.org/10.1007/s11739-011-0669-5

  13. Waterworth, D. M., Talmud, P. J., Bujac, S. R., Fisher, R. M., Miller, G. J., & Humphries, S. E. (2000). Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arteriosclerosis, thrombosis, and vascular biology, 20(12), 2663–2669. https://doi.org/10.1161/01.atv.20.12.2663

  14. Wang, Y. E., Kirschke, C. P., Woodhouse, L. R., Bonnel, E. L., Stephensen, C. B., Bennett, B. J., Newman, J. W., Keim, N. L., & Huang, L. (2022). SNPs in apolipoproteins contribute to sex-dependent differences in blood lipids before and after a high-fat dietary challenge in healthy U.S. adults. BMC nutrition, 8(1), 95. https://doi.org/10.1186/s40795-022-00592-x

  15. World Health Organization. (2025, July 31). Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

  16. Yang, L., Zheng, B. & Gong, Y. Global, regional and national burden of ischemic heart disease and its attributable risk factors from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021. BMC Cardiovasc Disord 25, 625 (2025). https://doi.org/10.1186/s12872-025-05022-x

  17. National Center for Biotechnology Information. ClinVar; [VCV000518235.16], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000518235.16 (accessed Sept. 7, 2026).

  18. National Center for Biotechnology Information. ClinVar; [VCV000017904.19], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000017904.19 (accessed Sept. 7, 2026).

  19. National Center for Biotechnology Information. ClinVar; [VCV000128418.49], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000128418.49 (accessed Sept. 7, 2026).

  20. National Center for Biotechnology Information. ClinVar; [VCV000001550.44], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000001550.44 accessed Sept. 7, 2026).

  21. National Center for Biotechnology Information. ClinVar; [VCV000001534.21], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000001534.21 (accessed Sept. 7, 2026).

Mualliflar haqida

Malika U.Yaxyoeva
myakh39@outlook.com
Respublika ixtisoslashtirilgan Kardiologiya ilmiy-amaliy tibbiyot markazi
Rano B.Alieva
ranoalieva@mail.ru
Respublika ixtisoslashtirilgan Kardiologiya ilmiy-amaliy tibbiyot markazi
Aleksandr B.Shek
shek-999@mail.ru
Respublika ixtisoslashtirilgan Kardiologiya ilmiy-amaliy tibbiyot markazi
A.V. Bahachova
bahachovaan@gmail.com
Belarusian State University

Litsenziya

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Qanday iqtibos keltirish kerak

Yurak ishemik kasalligi bilan og‘rigan bemorlarda lipid almashinuvining genetik variantlari bilan triglitseridlarga boy lipoproteinlar darajasi va aralash dislipidemiya o‘rtasidagi o‘zaro bog‘liqlikni baholash. (M. Yaxyoeva, R. Alieva, A. Shek, & A. Bahachova, Trans.). (2026). O’ZBEKISTON KARDIOLOGIYASI, 3(3), 11-21. https://doi.org/10.70626/cardiouz-2026-3-00094
Crossref
Scopus
Google Scholar
Europe PMC

Ushbu muallif(lar)ning eng koʻp oʻqilgan maqolalari

O'xshash maqolalar

Siz ham ushbu maqola uchun {$ advancedSearchLink} olishingiz mumkin.

ISSN 3060-4850 (Print)